LCTX - Lineage Cell Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

164.3M

Cash

45.93M

Avg Qtr Burn

-7.823M

Short % of Float

4.68%

Insider Ownership

4.42%

Institutional Own.

41.06%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OpRegen® (RPE Cells) Details Dry eye disease , Age-related macular degeneration	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
VAC2 (Dendritic Cells) Details Non-small cell lung carcinoma, Lung cancer, Lung disease	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OPC1 (Oligodendrocytes) Details Spine disorder, Spinal cord injury	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.